Form D · Biotechnology
Hexamer Therapeutics, Inc
Pullman, WA · CIK 0001797915
Offering snapshot reported Sep 15, 2026 · SEC filing
- Reported sold
- $500K Offering amount: $2.5M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 7, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 15, 2026 | Initial | $500,000 | No comparison | 2 | SEC filing |
| Jun 27, 2024 | Initial | $651,265 | No comparison | 9 | SEC filing |
| Dec 27, 2019 | Initial | $469,725 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-597517
Source: Form D, filed Sep 15, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| R. Scott Blackley | Director |
| Robert H Bogden | Director, Executive |
| Brad Call | Director |
| Colin Collins | Director |
| Stephen Crawford | Director |
| Keith Miller | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2345 Ne Hopkins Ct
Pullman, WA, 99163
Phone: 509-715-9251
Pullman, WA, 99163
Phone: 509-715-9251